Investment
Features
FeesSafety
Academy
More
Pluang+

North American Construction shifts focus to Australia, boosting revenue but raising debt concerns

Company Fundamentals
13 Sep 2026
Seeking Alpha
View Source
Neutral
North American Construction shifts focus to Australia, boosting revenue but raising debt concerns

North American Construction has transformed its business by acquiring MacKellar and IMC, shifting 75% of its revenue base to Australia. This move provides broader commodity exposure, reduces seasonality, and offers significant growth potential compared to its legacy Canadian operations. While the IMC acquisition increased revenue and EBITDA, it also pressured profit margins and raised leverage, making sustainable free cash flow generation a critical factor to watch in the second half of the year. The company's discounted cash flow model indicates attractive upside, but execution risks remain if EBITDA growth does not convert into free cash flow amid high debt and capital expenditure demands.

More News

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...

Company Fundamentals
Neutral
13 minutes ago
Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...

Analyst Insights
Bullish
1 hour ago
Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...

Analyst Insights
Bullish
1 hour ago
Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...

Analyst Insights
Bullish
2 hours ago
$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App